{
    "clinical_study": {
        "@rank": "166448", 
        "arm_group": [
            {
                "arm_group_label": "tauroursodeoxycholic", 
                "arm_group_type": "Experimental", 
                "description": "tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after  meal"
            }, 
            {
                "arm_group_label": "ursodeoxycholic", 
                "arm_group_type": "Active Comparator", 
                "description": "control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal"
            }
        ], 
        "brief_summary": {
            "textblock": "Though ursodeoxycholate acid (UDCA) is the well known effective therapy for PBC,clinical\n      effectiveness of UDCA may be limited by its poor absorption and extensive\n      biotransformation.The more hydrophillic bile acid tauroursodeoxycholate (TUDCA) is the\n      active ingredients of UDCA,and has been approved by state food and drug administration in\n      China for treatment of cholesterol stones.So it is necessary to verify the efficacy and\n      safety of TUDCA in the treatment of adult primary biliary cirrhosis. In this randomized,\n      double-blinded, double -dummy, parallel-controlled and multicenter clinical trial, we detect\n      the proportion of patients who had AKP decline more than 25% as the primary outcome;decline\n      of ALP,total bilirubin, GGT,ALT and AST as secondary outcomes after patients were treated\n      with TUDCA or UDCA for 24 weeks."
        }, 
        "brief_title": "Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Cholestatic Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Liver Diseases", 
                "Cholestasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, randomized, parallel controlled, multicenter, clinical trial.\n      Subjects inclusion by randomization after passing the screening, continuous administration\n      the test drug (Taurolite) or control drug (Ursofalk) treatment for 24 weeks. Compare the\n      safety and efficacy of Taurolite vs Ursofalk.\n\n      At the end of the double-blind period\uff0cenroll 100 subjects from both two group randomly ,for\n      a consecutive treatment use TUDCA up to 24 weeks. Further evaluate the efficacy and safety\n      of tauroursodeoxycholic acid (TUDCA) in the treatment of adult primary biliary cirrhosis\n      (PBC) for a long time up to one year. Also evaluate the regimen's efficacy and safety  that\n      udca take placed by TUDCA in the treatment of adult primary biliary cirrhosis (PBC) for the\n      patients who use udca treatment for 24 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1 Ages Eligible for Study:   18 Years to 70 Years\n\n             2 Alkaline phosphatase (ALP) \u2265 2 times the Upper Limits of Normal (ULN);\n\n             3 Anti mitochondrial antibody (AMA) positive and / or anti-mitochondrial antibody\n             subtype M2 (AMA-M2) positive; if the AMA and AMA-M2 were negative, need liver biopsy\n             confirmed pathological changes in PBC.\n\n        Exclusion Criteria:\n\n          -  1\uff0ein the 3 months before screening received UDCA, hormones, immunosuppressive\n             therapy;\n\n             2\uff0ewith extrahepatic biliary obstruction;\n\n             3\uff0eaccompanied by hepatitis B virus (HBV) and hepatitis C virus (HCV) infection;\n\n             4\uff0elaboratory screening examination :\n\n               1. hemoglobin (HB): male< 11 g/dL, female <10 g/dL < g/dL;\n\n               2. the total white blood cell (WBC) count < 3000/mm3;\n\n               3. the absolute neutrophil count (ANC) <1500/mm3;\n\n               4. platelet (PLT) count <50000/mm3;\n\n               5. serum albumin <3.3g/dL;\n\n               6. alanine aminotransferase (ALT) \u2265 10 ULN and / or aspartate aminotransferase\n                  (AST) \u2265 10ULN;\n\n               7. ALT \u2265 5 ULN and / or AST \u2265 5 ULN with immunoglobulin G (IgG) \u2265 2ULN;\n\n               8. total bilirubin (T-Bil) \u2265 4 ULN;\n\n               9. prothrombin time (PT) prolonged \u2265 3 seconds (limit reference value based on) or\n                  PTA \u2264 60%;\n\n              10. the serum creatinine (Cr) \u2265 1.5ULN.\n\n             5\uff0epatients with esophageal variceal or  bleeding, ascites, hepatic encephalopathy or\n             other evidence of hepatic decompensation;\n\n             6\uff0ediagnosed with liver cancer, suspected to have liver cancer, AFP > 100ng/ml. As the\n             AFP in 2 times the upper limit of normal to 100ng/ml, need re-check in 2 weeks, if\n             their AFP > 100ng/ml can not be included\n\n             7\uff0ebody mass index >28 (Kg/m2);\n\n             8\uff0ealcohol or drug abusers within the recent year;\n\n             9\uff0ethere is a serious heart, lung, kidney, digestive, nervous, mental disease,\n             autoimmune diseases or malignant tumor\n\n             10\uff0edrug-induced liver injury;\n\n             11. plan to transplant or have had organ transplants;\n\n             12\uff0e are unable or unwilling to provide informed consent or fails to comply with the\n             test requirements;\n\n             13\uff0epregnant,  lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "199", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829698", 
            "org_study_id": "Trendful-TAU-001", 
            "secondary_id": "2009L05707"
        }, 
        "intervention": [
            {
                "arm_group_label": "tauroursodeoxycholic", 
                "description": "Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after  meal", 
                "intervention_name": "tauroursodeoxycholic", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TUDCA", 
                    "Taurolite"
                ]
            }, 
            {
                "arm_group_label": "ursodeoxycholic", 
                "description": "ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal", 
                "intervention_name": "ursodeoxycholic acid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "UDCA", 
                    "Ursofalk"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ursodeoxycholic Acid", 
                "Tauroursodeoxycholic acid", 
                "Taurochenodeoxycholic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "tudca PBC Cholestasis tauroursodeoxycholic acid taurolite", 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100050"
                }, 
                "name": "Liver Research Center,Beijing Friendship Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluate the Efficacy And Safety Of TUDCA Compare UDCA In The Treatment Of Cholestatic Liver Disease-PBC by A Randomized,Double-Blind,Double Dummy,Parallel-Controlled,Multicenter Trial and The Consecutive Treatment By TUDCA", 
        "overall_official": [
            {
                "affiliation": "Beijing Friendship Hospital", 
                "last_name": "Ji Dong Jia, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Beijing Ditan Hospital", 
                "last_name": "Wen Xie, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Beijing YouAn Hospital Capital Medical University", 
                "last_name": "Hui Ping Yan, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "302 Military Hospital Of China", 
                "last_name": "Guo Feng Chen, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Peking University First Hospital", 
                "last_name": "Gui Qiang Wang, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Peking University People's Hospital", 
                "last_name": "Lai Wei, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Chinese PLA General Hospital", 
                "last_name": "Liu Fang Cheng, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "RenJi Hospital Affiliated To Shanghai Jiao Tong University School of Medicine", 
                "last_name": "Min De Zeng", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "RuiJin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine", 
                "last_name": "Qing Xie, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Affiliated HuaShan Hospital of Fudan University", 
                "last_name": "Guang Feng Shi, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Affiliated Zhongshan Hospital of Fudan University", 
                "last_name": "Ji Yao Wang, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Shanghai Changzheng Hospital", 
                "last_name": "Xiao Hui Miao, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "No.85 hospital of PLA", 
                "last_name": "Cheng Wei Chen, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Shanghai Public Health Clinical Center", 
                "last_name": "Shan Ming Wu, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Shanghai Eastern Hepatobiliary Surgery Hospital", 
                "last_name": "He Ping Hu, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "The First Affiliated Hospital,SunYat-Sen University", 
                "last_name": "Min Hu Chen, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "The Third Affiliated Hospital,SunYat-Sen University", 
                "last_name": "Zhi Liang Gao, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Affiliated Southern Hospital of Southern Medical University", 
                "last_name": "Jin Lin Hou, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "The First Affiliated Hospital of Medical College,Zhejiang University", 
                "last_name": "Ji Fang Sheng, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "NO.6 People's Hospital of Hangzhou", 
                "last_name": "Xiao Qing Fu, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Affiliated Huaxi Hospital of Sichuan University", 
                "last_name": "Hong Tang, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "The First Affiliated Hospital Of The Fourth Military Medical University", 
                "last_name": "Ying Han, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Affiliated TongJi Hospital Of Tongji Medical College Huazhong University Of Science&Technology", 
                "last_name": "Qin Ning, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "The First Affiliated Hospital of Kunming Medical College", 
                "last_name": "Li Ping Duan, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "NO.3 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine", 
                "last_name": "Jie Xu, Doctor", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "After 24 weeks of treatment, calculate the rate of  patients whose ALP level of serum ALP decreased more than 25% compared to the baseline. After 48 weeks of treatment, calculate the rate of  patients whose ALP level of serum ALP decreased more than 40% compared to the baseline.", 
            "measure": "Efficiency is defined as the patients composition whose  ALP level of serum decreased more than 25% compared to baseline at treatment for 24 weeks.", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829698"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "after 24 weeks of treatment, the serum level ALP decreased compared with baseline.\nafter 24 weeks of treatment, the serum bilirubin level decreased compared with baseline.\nafter 24 weeks of treatment, the serum level of GGT decreased compared with baseline.\nafter 24 weeks of treatment, serum ALT, AST levels decreased compared to baseline.\nafter 48 weeks of treatment, the serum level ALP decreased compared with 24 weeks.\nafter 48 weeks of treatment, the serum level ALP decreased compared with baseline.\nafter 48 weeks of treatment, the serum bilirubin level decreased compared with 24 weeks.\nafter 48 weeks of treatment, the serum level of GGT decreased compared with 24 weeks.\nafter 48 weeks of treatment, serum ALT, AST levels decreased compared to 24 weeks.", 
            "measure": "The change of laboratory parameters about liver function", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "source": "Beijing Trendful Kangjian Medical Information Consulting Limited Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Trendful Kangjian Medical Information Consulting Limited Company", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}